zintick
INM InMed PharmaceuticalsCorporate actionStock splits

InMed Pharmaceuticals Completes 1-for-10 Reverse Stock Split; Trading Expected Nov. 5

Split-adjusted shares are expected to trade on Nasdaq under the existing INM symbol with a new CUSIP.

By Zintick Team · Editor: Kratik Mehta
Published

scientist with mask, glasses and gloves checking hemp plants in a greenhouse. Concept of herbal alternative medicine, cbd oil
Photo: Blue Titan/Shutterstock.com

Key terms

  • 1-for-10 reverse split; shares outstanding fell from 5,493,735 to about 549,374
  • Split-adjusted trading expected to begin at the start of trading on Nov. 5, ticker remains INM
  • New CUSIP 457637809 and ISIN CA4576378091; fractions rounded, no cash paid
  • Company renamed Mentari Therapeutics, Inc. the same day

InMed Pharmaceuticals Inc. (Nasdaq: INM) completed a 1-for-10 reverse stock split, the company said in an 8-K accepted Thursday, Nov. 5, 2026.

The same day, the company changed its legal name to Mentari Therapeutics, Inc. At its annual general and special meeting held Nov. 4, shareholders approved the Nasdaq Share Issuance Proposal, which covers share issuance and a change of control tied to the company's pending merger with Mentari, according to a separate 8-K filed the same day.

The consolidation was completed after the company's annual general and special meeting, held Nov. 4. Each 10 pre-consolidation common shares became one post-consolidation share. Shares outstanding fell from 5,493,735 to approximately 549,374. The stock closed at $1.75 on Nov. 4, the last close before the filing.

Trading and ticker

Effective at the start of trading on Nov. 5, common shares are expected to trade on The Nasdaq Capital Market on a post-consolidation basis. The ticker remains INM. The new CUSIP number is 457637809 and the new ISIN is CA4576378091.

Fractional shares

Fractional shares were rounded to the nearest whole share: up if 0.5 or greater, down if less than 0.5. No cash or other consideration was paid for rounding. The filing does not give a record date for the split.

Outstanding stock options and warrants were adjusted proportionately, as were their exercise prices. The number of shares reserved under the company's equity incentive plan was reduced in the same proportion. The filing does not state why the company carried out the consolidation.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

More corporate actions

Reverse stock splits and stock splits →
INM page →

Filings, figures and price history are on the InMed Pharmaceuticals page.